A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Phase 1/2
55
about 15 years
18+
1 site in KY
About this study
This trial is testing the safety of Vemurafenib combined with Metformin in melanoma patients. The phase II part will also evaluate how well this combination works (clinical activity) for people with metastatic melanoma.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Metformin
- 2.Take Vemurafenib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
metformin (Biguanide antidiabetic; reduces liver glucose production and improves insulin sensitivity), vemurafenib
oral
Primary: Observation of CTCAE grade 4 or higher adverse events in six patients
Secondary: Number of adverse events, Objective response rate (ORR)as measure of efficacy, Overall Survival Follow up, type of adverse events
Oncology